Be careful about MICs to amoxicillin for patients with Streptococci-related infective endocarditis.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 04 01 2019
revised: 18 02 2019
accepted: 02 03 2019
pubmed: 10 3 2019
medline: 3 9 2019
entrez: 10 3 2019
Statut: ppublish

Résumé

A variety of microorganisms can cause infective endocarditis (IE), with Staphylococci and Streptococci accounting for the majority of cases. Streptococci are a common cause of community-acquired IE but few studies have focused on this subgroup of endocarditis. A retrospective multicentre study was conducted between 2012 and 2017 in 12 hospital centres in France. Data were extracted from the local diagnosis-related group database and matched with microbiological results. After identification, the records were retrospectively analysed. A total of 414 patients with streptococcal endocarditis were included. The patients were predominantly male (72.8%) and the median age was 73.2 years (interquartile range [IQR] 61.3-80.9). The majority of patients (70.6%) had native valve endocarditis. Embolic complications were seen in 38.8% of patients. Viridans group Streptococci (VGS) and bovis-equinus group Streptococci (BGS) accounted for 52.4% and 34.5% of isolated strains, respectively. Minimum inhibitory concentrations (MICs) of amoxicillin were <0.125, 0.125-2 and >2 mg/L for 59.6%, 27% and 1% of isolates, respectively. In-hospital mortality for patients with Streptococci-related IE was 17.8%. In multivariate analysis, the only factor associated with in-hospital mortality was MIC for amoxicillin between 0.25 and 2 mg/L (P = 0.04; OR = 2.23 [95% confidence interval (CI) 1.03-4.88]) whereas performance of cardiac surgery for IE was a protective factor (P = 0.001, OR = 0.23 [95% CI 0.1-0.56]). IE remains a serious and deadly disease despite recent advances in diagnosis and treatment. Adaptation of antibiotic doses to MICs for amoxicillin and surgery may improve patient outcome.

Sections du résumé

BACKGROUND BACKGROUND
A variety of microorganisms can cause infective endocarditis (IE), with Staphylococci and Streptococci accounting for the majority of cases. Streptococci are a common cause of community-acquired IE but few studies have focused on this subgroup of endocarditis.
METHODS METHODS
A retrospective multicentre study was conducted between 2012 and 2017 in 12 hospital centres in France. Data were extracted from the local diagnosis-related group database and matched with microbiological results. After identification, the records were retrospectively analysed.
RESULTS RESULTS
A total of 414 patients with streptococcal endocarditis were included. The patients were predominantly male (72.8%) and the median age was 73.2 years (interquartile range [IQR] 61.3-80.9). The majority of patients (70.6%) had native valve endocarditis. Embolic complications were seen in 38.8% of patients. Viridans group Streptococci (VGS) and bovis-equinus group Streptococci (BGS) accounted for 52.4% and 34.5% of isolated strains, respectively. Minimum inhibitory concentrations (MICs) of amoxicillin were <0.125, 0.125-2 and >2 mg/L for 59.6%, 27% and 1% of isolates, respectively. In-hospital mortality for patients with Streptococci-related IE was 17.8%. In multivariate analysis, the only factor associated with in-hospital mortality was MIC for amoxicillin between 0.25 and 2 mg/L (P = 0.04; OR = 2.23 [95% confidence interval (CI) 1.03-4.88]) whereas performance of cardiac surgery for IE was a protective factor (P = 0.001, OR = 0.23 [95% CI 0.1-0.56]).
CONCLUSIONS CONCLUSIONS
IE remains a serious and deadly disease despite recent advances in diagnosis and treatment. Adaptation of antibiotic doses to MICs for amoxicillin and surgery may improve patient outcome.

Identifiants

pubmed: 30851401
pii: S0924-8579(19)30054-8
doi: 10.1016/j.ijantimicag.2019.03.002
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Amoxicillin 804826J2HU

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

850-854

Investigateurs

V Cattoir (V)
S Corvec (S)
D Boutoille (D)
G Péan de Ponfilly (GP)
S Reissier (S)

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

B Pilmis (B)

Equipe mobile de microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France. Electronic address: bpilmis@hpsj.fr.

J Lourtet-Hascoët (J)

Laboratoire de microbiologie clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France.

O Barraud (O)

Université Limoges, INSERM, CHU Limoges, UMR 1092, Limoges, France.

C Piau (C)

Service de Bactériologie-Hygiène hospitalière, CHU de Rennes, Rennes, France.

C Isnard (C)

Service de Microbiologie, CHU de Caen, Caen F-14033, France.

G Hery-Arnaud (G)

Département de Microbiologie, CHRU Brest, Brest, France.

M Amara (M)

Service de Biologie, Unité de Microbiologie, Centre Hospitalier de Versailles, Le Chesnay, France.

A Merens (A)

Service de Microbiologie, Hôpital inter-armées Bégin, Saint-Mandé, France.

E Farfour (E)

Service de Biologie Clinique, Hôpital Foch, Suresnes, France.

E Thomas (E)

Service de Bactériologie-Hygiène Hospitalière, Nantes, France.

H Jacquier (H)

Service de Bactériologie, Hôpital Lariboisière, Paris, France.

J-R Zahar (JR)

Unité de prévention et de lutte contre les infections nosocomiales, Hôpital Avicennes, Bobigny, France.

E Bonnet (E)

Equipe mobile d'infectiologie, Clinique Pasteur Toulouse, Toulouse, France.

A Le Monnier (AL)

Laboratoire de microbiologie clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH